The pharmaceutical development lifecycle: from discovery to patient access

Discovery and preclinical development

Discovery teams identify and test biological targets and potential therapeutic approaches. Preclinical work investigates pharmacology, toxicology, formulation and manufacturing feasibility before testing in people. Translational science connects laboratory findings to biomarkers and clinical hypotheses.

Portfolio decisions at this stage weigh scientific rationale, unmet need, technical risk, differentiation and development feasibility. Most early candidates do not progress, so learning and evidence quality matter as much as speed.

Clinical trial phases

Early clinical studies commonly focus on safety, tolerability, dose and initial biological activity. Later studies test efficacy and safety in larger, more defined populations. Phase labels are helpful shorthand but do not capture every design, particularly in oncology, rare disease and advanced therapies.

Clinical development, operations, biostatistics, data management, safety, regulatory and manufacturing teams work together to produce reliable evidence while protecting participants.

Regulatory review and approval

Regulators assess quality, safety and efficacy using the submitted evidence package. Approval defines the authorised indication and conditions of use. It does not automatically determine price, reimbursement or adoption within a healthcare system.

After approval, companies maintain licences, manage variations, monitor safety and continue evidence generation. Labelling and risk-management obligations can evolve as new information emerges.

HTA, reimbursement and launch

Health technology assessment bodies and payers may evaluate comparative benefit, cost effectiveness, budget impact and implementation. The evidence needed can differ from the regulatory package, making early access and HEOR planning important.

Launch readiness coordinates supply, medical education, access, field capability, customer engagement and governance. A regulatory milestone may create work across several functions, but it is not proof that an organisation is currently hiring.

Lifecycle management

Once a medicine is available, teams monitor outcomes, safety, utilisation and changing standards of care. New formulations, indications, populations or geographies may require additional evidence and approvals.

For career planning, lifecycle stage matters. An early biotech may prioritise development and financing capabilities, while a launch-stage affiliate may need access, medical, commercial and supply leadership.

Map career evidence to lifecycle decisions

Draw the stages relevant to your experience and place each major achievement under the decision it supported: candidate selection, protocol, evidence readout, submission, authorisation, reimbursement, launch, safety monitoring or lifecycle change. Some work will span stages; record the actual hand-off rather than forcing a linear story.

Add the controlled output and stakeholders for each achievement. This reveals transferable patterns such as evidence interpretation, risk management or cross-functional governance while preserving the scientific and regulatory setting in which the work occurred.

How to read an industry event

When a trial, regulatory or access milestone is announced, confirm the source, date, jurisdiction, product and exact decision. Identify the next plausible stage and functions commonly involved, but do not convert that inference into a claim that a company is hiring.

Separate immediate operational work from longer-term possibilities. A positive opinion, approval and reimbursement recommendation are different events. Career monitoring becomes more useful when it records those boundaries and waits for direct vacancy or organisation evidence before asserting an opportunity.

Sources and further reading

Authoritative sources support the regulated or employment context. The practical framework and interpretation are original PTTF editorial work.

1. Human medicines in the product lifecycle — European Medicines Agency
2. Compliance in the product lifecycle — European Medicines Agency
3. Pharmacovigilance overview — European Medicines Agency